Zeria Pharmaceutical Co Ltd
TSE:4559
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Digi International Inc
NASDAQ:DGII
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (5), the stock would be worth ¥2 568.72 (17% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.3 | ¥2 187 |
0%
|
| 3-Year Average | 5 | ¥2 568.72 |
+17%
|
| 5-Year Average | 6.4 | ¥3 259.95 |
+49%
|
| Industry Average | 10.6 | ¥5 404.11 |
+147%
|
| Country Average | 8.7 | ¥4 414.62 |
+102%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
¥77.9B
|
/ |
Jan 2026
¥17.8B
|
= |
|
|
¥77.9B
|
/ |
Mar 2026
¥17.9B
|
= |
|
|
¥77.9B
|
/ |
Mar 2027
¥19.9B
|
= |
|
|
¥77.9B
|
/ |
Mar 2028
¥21B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
|
Zeria Pharmaceutical Co Ltd
TSE:4559
|
96.4B JPY | 4.3 | 13.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 28.4 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 16.9 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 15.6 | 28.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 12.2 | 19.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 9.7 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8.2 | 11.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 7.5 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 7.2 | 16.8 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 6.7 |
| Median | 8.7 |
| 70th Percentile | 12.2 |
| Max | 214 699 781.2 |
Other Multiples
Zeria Pharmaceutical Co Ltd
Glance View
Zeria Pharmaceutical Co., Ltd. engages in the manufacture, sale, import and export of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 1,690 full-time employees. The firm operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
